Author(s)

Onur Eroglu^1,2*, Hacer Kaya¹, Esin Guvenir Celik¹, Merve Celen³, Elif Korkut⁴, Nagihan Nizam¹

¹Department of Molecular Biology and Genetics, Faculty of Science and Letters, Bilecik Seyh Edebali University, Bilecik, Turkey.
²Biotechnology Research and Application Center, Bilecik Seyh Edebali University, Bilecik, Turkey.
³Vocational School of Medical Services, Program of Medical Laboratory Techniques, Bilecik Seyh Edebali University, Bilecik, Turkey.
⁴Department of Medical Genetics, Faculty of Medicine, Baskent University, Ankara, Turkey.

Purpose: Investigating the triple effect of doxorubicin, 5-fluorouracil, propranolol on MCF-7 (ER+, WTp53) breast cancer cell line with MTT test and survival analysis. Materials/Methods: In order to determine effective dosages of a combination of doxorubicin, 5-fluorouracil, propranolol on the MCF-7 cell line by using MTT and survival analysis technique. Result: IC₅₀ values acquired by MTT tests are 0.01 mg/ml for doxorubicin, 6 mg/ml for 5-fluorouracil, 30 mg/ml for propranolol and 0.2/1/30 mg/ml (with previous respect) if all three agents are combined. It is found that the use of doxorubicin, 5-fluorouracil, and propranolol in combination is much effective than their single application. Discussion: Moderate concentrations of doxorubicin, 5-fluorouracil, and propranolol, if they are applied individually, showed high toxicity. When we used these drugs in combination; toxic effects lessened with respect to monotherapy. In the MCF-7 cell line, doxorubicin (IC₅₀: 0.01 μM) increases cell death rates significantly and propranolol (IC₅₀: 3 μM) has minimum effects in monotherapy in contrast to others. Propranolol is only superior to itself in combination therapy (IC₅₀: 4 μM). However 5-fluorouracil (IC₅₀: 30 μM) showed antagonistic effects with respect to other drugs. Additionally, having applied the three drugs in combination on the MCF-7 cell line for the first time in literature, it is highly possible to assess the application of doxorubicin, 5-fluorouracil and propranolol combination as a novel therapy option.

MCF-7, Breast Cancer, Combine Treatment, Doxorubicin, 5-Fluorouracil, Propranolol

Eroglu, O. , Kaya, H. , Celik, E. , Celen, M. , Korkut, E. and Nizam, N. (2019) Triple Effect of Doxorubicin, 5-Fluorouracil, Propranolol on Cell Survival on MCF-7 Breast Cancer Cell Line. Journal of Biosciences and Medicines, 7, 74-85. doi: 10.4236/jbm.2019.72007.